KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Amortization of Deferred Charges: 2017-2025

Historic Amortization of Deferred Charges for Emergent BioSolutions (EBS) over the last 8 years, with Sep 2025 value amounting to $2.5 million.

  • Emergent BioSolutions' Amortization of Deferred Charges rose 137.31% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year decrease of 13.76%. This contributed to the annual value of $7.4 million for FY2024, which is 65.26% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Amortization of Deferred Charges stood at $2.5 million, which was up 4.17% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Amortization of Deferred Charges ranged from a high of $8.9 million in Q2 2023 and a low of -$6.7 million during Q3 2024.
  • In the last 3 years, Emergent BioSolutions' Amortization of Deferred Charges had a median value of $2.5 million in 2025 and averaged $3.3 million.
  • Per our database at Business Quant, Emergent BioSolutions' Amortization of Deferred Charges spiked by 790.00% in 2023 and then crashed by 217.54% in 2024.
  • Emergent BioSolutions' Amortization of Deferred Charges (Quarterly) stood at $1.0 million in 2021, then remained steady at $1.0 million in 2022, then skyrocketed by 470.00% to $5.7 million in 2023, then tumbled by 61.40% to $2.2 million in 2024, then skyrocketed by 137.31% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $2.4 million for Q2 2025, and $2.3 million during Q1 2025.